about
γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current StatusVitamin E Analogs as Radiation Response ModifiersAcute radiation syndrome caused by accidental radiation exposure - therapeutic principlesVitamin E: tocopherols and tocotrienols as potential radiation countermeasuresHemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primatesRandomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation.Synergistic radioprotection by gamma-tocotrienol and pentoxifylline: role of cAMP signalingEvaluation of the fullerene compound DF-1 as a radiation protector.Pharmacological potential of tocotrienols: a review.ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway.In vitro metabolism and stability of the actinide chelating agent 3,4,3-LI(1,2-HOPO).Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.Radiation countermeasure agents: an update (2011-2014)Radiation damage to the lung: mitigation by angiotensin-converting enzyme (ACE) inhibitorsDecreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.Tocotrienol-Rich Fraction from Rice Bran Demonstrates Potent Radiation Protection ActivityPersonalized Radioproteomics: Identification of a Protein Biomarker Signature for Preemptive Rescue by Tocopherol Succinate in CD34(+) Irradiated Progenitor Cells Isolated from a Healthy Control Donor.Neuroprotective effect of acute melatonin treatment on hippocampal neurons against irradiation by inhibition of caspase-3Non-erythropoietic tissue-protective peptides derived from erythropoietin: WO2009094172.A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute.Animal models for acute radiation syndrome drug discovery.Evaluation of gamma ray-induced gastrointestinal tract morphological and proliferative activity changes in rhesus monkeys.Nonhuman primates as models for the discovery and development of radiation countermeasures.A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.Synthesis and radioprotective properties of pulvinic acid derivatives.Low-dose photon and simulated solar particle event proton effects on Foxp3+ T regulatory cells and other leukocytes.Vitamin D protects endothelial cells from irradiation-induced senescence and apoptosis by modulating MAPK/SirT1 axis.Analysis of a metalloporphyrin antioxidant mimetic (MnTE-2-PyP) as a radiomitigator: prostate tumor and immune status.Alpha-tocopherol succinate-mobilized progenitors improve intestinal integrity after whole body irradiation.Space-relevant radiation modifies cytokine profiles, signaling proteins and Foxp3+ T cells.Antioxidant Tocols as Radiation Countermeasures (Challenges to be Addressed to Use Tocols as Radiation Countermeasures in Humans).
P2860
Q26751505-C3CFF985-DF04-4492-87BA-9C26BA63CE0BQ26781114-B9BC3845-6984-44AD-877F-1BE6D8E26EFAQ27021962-3B9ED70C-889F-43E4-B436-FB01B7A67077Q28290335-5150F0BC-98F9-4C48-8313-CA347C0943C1Q28731776-1E4A939D-EF0C-433E-84BD-73EFC3EE15AEQ33414472-94EE81DA-7B3C-4D0C-9103-E6A57CDDD6F2Q33711181-99180383-F486-403B-9A55-7CD8074E93BAQ33881319-5AB51288-9E04-4091-8D20-8D8DEC11EF72Q34450166-837C543D-00BA-4DB7-8812-967596AF620AQ34625756-F6D504AB-1692-436C-954E-F7889B2030AEQ35328658-D8775C65-241A-4841-8303-B69211C6FC95Q35566671-B21B4197-6754-4869-8992-57A20D34460AQ35626587-FCD389E3-B80C-4226-B347-ADD0714F6760Q35631661-5AC4335C-2487-4E93-9CDE-E45A3002D861Q35878951-0BAECD4C-1253-4B6B-B6A6-72F9AC7EDB2DQ36070511-DECC7779-74A5-4ECB-B285-331D8BF89992Q36802901-1CAD5D1E-3EB2-4E4F-87A9-10635C39D50EQ36954056-EFE77D1B-DCD6-44B6-900B-387FC1AC5746Q37700755-8A221C8F-3D12-4CA7-BDF6-55A016818E75Q37970729-6AF078E5-6091-4003-81C4-85F44949CCEBQ38394740-6E8D86B5-B8B0-4938-8290-A2BFD2D7AD42Q38928542-1F6A8F9E-7785-40CE-86A6-33F5B6ADA9B7Q39261890-535358D0-3B0B-4B22-B1F0-0B01BB4B7302Q39398444-AEAE3DA3-9E6F-4454-BDA8-34D70BAEB90FQ39605917-860BBD42-C8F7-4E57-AA23-217209CBE493Q44461018-280EED5D-AB95-42C7-8B0B-C4A1FD656C41Q46675123-584C0639-6D74-465D-9042-3F8B6AF32A30Q48704271-0CADBAD5-88BD-4A48-9C65-29547B6E7301Q53127699-683005A8-A016-46A4-8981-24CCB478742CQ54493452-6AE5DCC7-7163-4973-BA35-85E489545B1FQ55177665-F7EF56C3-B7DC-4EA3-ADCA-630421F21FC1
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Radiation countermeasure agents: an update.
@en
Radiation countermeasure agents: an update.
@nl
type
label
Radiation countermeasure agents: an update.
@en
Radiation countermeasure agents: an update.
@nl
prefLabel
Radiation countermeasure agents: an update.
@en
Radiation countermeasure agents: an update.
@nl
P2093
P2860
P1476
Radiation countermeasure agents: an update.
@en
P2093
Antoine Le Roux
Francis Dumont
Pierre Bischoff
P2860
P304
P356
10.1517/13543770903490429
P407
P577
2010-01-01T00:00:00Z